INSIGHTS ON SOLID DOSE MANUFACTURING
-
How To Avoid Sticking And Picking In The Tableting Industry
Review strategies to mitigate sticking and picking risks in the tablet industry, and learn how you can foster improved tablet production processes, ensuring higher quality and consistency.
-
Optimising Solubility: Selecting The Right Technology For Early Drug Development
Discover how selecting the right solubility‑enhancing technology improves early exposure, supports flexible dosing, and lays a strong foundation for downstream oral drug development.
-
Raise Your Standards With Downflow Booth Airflow Containment
Ensure personnel safety during hazardous material handling by mastering airflow dynamics and containment screens. Learn to achieve low exposure levels through advanced HEPA filtration methods.
-
Safely Scaling High Potency API Manufacturing
Scaling HPAPI production demands disciplined containment and exposure control. Integrated operating models help manage risk while enabling compliant, reliable scale‑up.
-
Orally-Disintegrating Dosage Forms With Taste Masked Multiparticulates7/17/2024
Learn more about our orally disintegrating tablet (ODT) capabilities and how these innovative technologies have the potential to improve acceptance, adherence, and compliance in pharmacotherapy.
-
Accelerating An Innovative High Potency Oncology Therapy To Market5/13/2026
Learn how disciplined containment, proactive risk management, and collaboration accelerate complex oncology programs under tight timelines while protecting quality, safety, and global launch readiness.
-
The Future Of Oral Solid Dose Development And Innovation2/27/2025
Tom Sellig, CEO of Adare, discusses the ongoing relevance of small molecules, oral solid dose development, trends like GLP-1, and innovations like 3D printing in pharmaceuticals.
-
The Role Of Quality By Design In Pharmaceutical Tablet Development7/30/2024
Quality by Design (QbD) ensures efficiency and high standards in pharmaceutical tablet development. Explore how this proactive approach transforms manufacturing processes and enhances product quality.
-
The Importance Of Tablet Density Uniformity10/7/2025
Non-uniform density causes many tablet failures. Learn how optimizing your formulation, tablet proportions, and tooling design ensures proper de-aeration for consistent quality.
SOLID DOSE MANUFACTURING SOLUTIONS
-
Basic Powder Flow Characterization [USP <1174>]:
A powder flow analysis is an indicator of how well formulation will release from the hopper during the tableting. It is important to know that the developed formulation is showing ‘Mass Flow’ or ‘Funnel Flow’ or ‘Rat Holing’.
Powder blend shows ‘Mass Flow’ when the entire solid bed is in motion during the discharge of material from the outlet. This is a ‘First-in-First-Out’ process. Hoppers offering ‘Mass Flow’ have steep and/or low-friction walls. This flow offers ‘No-Arching’, ‘Less Segregation’, and ‘Stable Powder Flow’.
When the hopper is not sufficiently steep and smooth enough to ensure sliding along its wall, the powder blend exhibit ‘Funnel Flow’. Such hoppers are sensitive to arching and ratholing. In this case, powder discharge from the hopper is not predictable.
-
Used Sejong Encapsulator, with change parts/tooling, 600 volts, 3 phase.
-
Hata Tablet Press, Model HT-AP55-DU/I.E. Double sided, serial number Nov. 90 - Oct. 1991
-
Partner with Natoli Scientific during the earliest stages. Our scientific expertise with state-of-the-art analytical capabilities is ready to take any preformulation challenge.
Natoli scientific has an expertise of handling a wide range of APIs for the development of oral solids. We apply principles of ‘Quality by Design’ to define Critical Material Attributes (CMA), Critical Process Parameters (CPP), Critical Quality Attributes (CQA) and Quality Target Product Profiles (QTPP). Because we believe that understanding material and process as much as possible in the early life cycle of drug product development program is an insurance for further development path. Keeping your practices up to date with the ICHQ8 regulatory guidance issued by the US FDA. This is also a gate way for a smooth ride of product in the different stages of product development stages.
-
Finding a strategic CDMO partner that will offer tailored solutions for your late phase clinical and commercial needs, mitigate risks, and bolster your supply chain is crucial for meeting project milestones on time.